This research focuses on canine lymphoma, a common cancer with tens of thousands of new cases each year in the United States. Standard chemotherapy often works at first, but the disease frequently returns within 12 months, so better, longer lasting options are urgently needed. A new treatment called chimeric antigen receptor T cell (CAR-T) therapy has shown great promise for human leukemia and lymphoma. Early studies in dogs are encouraging, but results have not yet matched the success in people. One reason may be that CAR-T cells do not stay active long enough in dogs to fully control the cancer. The goal of this study is to develop a next-generation CAR-T therapy by adding a protective feature that helps canine CAR-T cells survive longer and keep fighting the cancer. We will generate these “armored” CAR-T cells in the laboratory and test their ability to grow and eliminate canine lymphoma cells.